loading
Precedente Chiudi:
$1.93
Aprire:
$2
Volume 24 ore:
11,044
Relative Volume:
0.05
Capitalizzazione di mercato:
$71.66M
Reddito:
-
Utile/perdita netta:
$-41.36M
Rapporto P/E:
-1.2012
EPS:
-1.64
Flusso di cassa netto:
$-42.09M
1 W Prestazione:
-5.29%
1M Prestazione:
+37.08%
6M Prestazione:
-8.37%
1 anno Prestazione:
-27.04%
Intervallo 1D:
Value
$1.92
$2.0896
Intervallo di 1 settimana:
Value
$1.90
$2.1986
Portata 52W:
Value
$0.8981
$3.4154

Armata Pharmaceuticals Inc Stock (ARMP) Company Profile

Name
Nome
Armata Pharmaceuticals Inc
Name
Telefono
310-655-2928
Name
Indirizzo
4503 Glencoe Avenue, Marina del Rey, CA
Name
Dipendente
33
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-19
Name
Ultimi documenti SEC
Name
ARMP's Discussions on Twitter

Confronta ARMP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARMP
Armata Pharmaceuticals Inc
1.98 72.39M 0 -41.36M -42.09M -1.64
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.50 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.38 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.13 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
487.71 65.13B 14.09B 4.50B 2.96B 39.28

Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2019-06-19 Iniziato Ladenburg Thalmann Buy

Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie

pulisher
Jun 03, 2025

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha

Jun 03, 2025
pulisher
Jun 02, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 25, 2025

ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN

May 25, 2025
pulisher
May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025
pulisher
May 22, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

May 22, 2025
pulisher
May 22, 2025

Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World

May 22, 2025
pulisher
May 20, 2025

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus

May 19, 2025
pulisher
May 19, 2025

ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata reports data from Phase 1b/2a diSArm trial - TipRanks

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus

May 19, 2025
pulisher
May 19, 2025

ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire

May 19, 2025
pulisher
May 15, 2025

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times

May 14, 2025
pulisher
May 05, 2025

Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World

May 05, 2025
pulisher
May 02, 2025

Armata Pharmaceuticals secures additional DoD funding - Investing.com

May 02, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance

May 01, 2025
pulisher
Apr 28, 2025

New Strong Sell Stocks for April 28th - The Globe and Mail

Apr 28, 2025
pulisher
Apr 01, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Bacteriophage Therapy Market Future Business Opportunities - openPR

Mar 31, 2025
pulisher
Mar 24, 2025

HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz

Mar 21, 2025
pulisher
Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire

Mar 20, 2025
pulisher
Mar 18, 2025

Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter

Mar 18, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress

Mar 12, 2025
pulisher
Mar 11, 2025

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow

Mar 11, 2025
pulisher
Feb 18, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat

Feb 18, 2025

Armata Pharmaceuticals Inc Azioni (ARMP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price up icon 0.56%
Capitalizzazione:     |  Volume (24 ore):